MediVector, Inc., a privately held drug development company in Boston, is being awarded a $138,500,000 contract under a DoD Joint Project Manager Transformation Medical Technologies (JPM-TMT) initiative for advanced development of emerging infectious diseases medical countermeasures for FDA licensure.
Specifically, the company will further develop Favipiravir (T-705), a broad-spectrum therapeutic against multiple influenza viruses, including pandemic and drug resistant strains.
“Currently available medical countermeasures do not adequately protect the Joint Force,” said David E. Hough, Joint Project Manager of JPM-TMT. “This drug shows promise that it can mitigate flu symptoms by interfering with the influenza replication process. Our contract with MediVector addresses a capability gap in the protection of the Joint Forces.”
The Defense Threat Reduction Agency, Fort Belvoir, Va., is the contracting activity (HDTRA1-12-C-0031). The solicitation was issued for full and open competition and four proposals were received. Work is expected to be completed April 2016.